On paper, there's tremendous potential for clinical-grade genetic testing to influence routine health decisions. The coronavirus pandemic is exposing the fact that, in reality, the practice is still ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

Invitae Corp (NYSE: NVTA) has agreed to acquire Genosity Inc, a genomics company offering software and laboratory solutions to enable the development and deployment of complex sequencing-based tests.

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Invitae is a growth leader in genetic testing. The company is growing at full speed, and it has enormous room for expansion going forward. Lack of profitability and share dilution are the main ...

What is a winner-take-most market? The long term profitability and success of any company is highly dependent on the market in which it operates. Many markets have low barriers to entry; many sellers ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae also recently launched a new service model that allows consumers to initiate and order health screening tests and receive genetic guidance through a telemedicine service. (Pixabay) Genetic ...

Invitae (NVTA) announced a $1.4 billion plan Monday to acquire genetic testing company ArcherDX in a deal that sent NVTA stock rocketing. The combination will bring various modes of genetic testing ...

BOSTON--(BUSINESS WIRE)--Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

In the past three months alone, shares of genetic testing company Invitae (NVTA +0.00%) have soared by 90%. In fact, the company's shares outperformed the S&P 500's return of 25% by nearly five times ...